Home » Topics » BioWorld Science, Immune

BioWorld Science, Immune
RSS

Preliminary phase II results in for VRI's adjuvanted influenza vaccine

Nov. 28, 1997

WB-2663B, a novel immunosuppressant isolated from Pseudomonas

Nov. 27, 1997

ImmuLogic restructures its operations

Nov. 26, 1997

Role of complement in mast cell-dependent natural immunity

Nov. 24, 1997

Topical FK-506 for skin allograft rejection

Nov. 21, 1997

New cytokine production inhibitors revealed by SS Pharm.

Nov. 21, 1997

FDA advisory committee to review rotavirus vaccine

Nov. 20, 1997

BCH-1393 stimulates CTL response in vitro and in vivo

Nov. 19, 1997

Basiliximab reduces renal allograft rejection in phase III trial

Nov. 19, 1997

Second report of clinical efficacy for rotavirus vaccine

Nov. 18, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...